2019-02472. National Cancer Institute; Notice of Meeting  

  • Start Preamble

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Cancer Institute Clinical Trials and Translational Research Advisory Committee.Start Printed Page 4487

    The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will also be videocast and can be accessed from the NIH Videocasting and Podcasting website (http://videocast.nih.gov/​).

    Name of Committee: National Cancer Institute Clinical Trials and Translational Research Advisory Committee.

    Date: July 17, 2019.

    Time: 8:00 a.m. to 4:00 p.m.

    Agenda: Strategic Discussion of NCI's Clinical and Translational Research Programs.

    Place: National Cancer Institute Shady Grove, East Wing, Seminar Room 110, 9609 Medical Center Drive, Rockville, MD 20850.

    Contact Person: Sheila A. Prindiville, MD, MPH Director, Coordinating Center for Clinical Trials, National Institutes of Health, National Cancer Institute, Coordinating Center for Clinical Trials, 9609 Medical Center Drive, Room 6W136, Rockville, MD 20850, 240-276-6173 prindivs@mail.nih.gov.

    Name of Committee: National Cancer Institute Clinical Trials and Translational Research Advisory Committee.

    Date: November 6, 2019.

    Time: 8:00 a.m. to 4:00 p.m.

    Agenda: Strategic Discussion of NCI's Clinical and Translational Research Programs.

    Place: National Cancer Institute Shady Grove, East Wing, Conference, Room TE406, 9609 Medical Center Drive, Rockville, MD 20850.

    Contact Person: Sheila A. Prindiville, MD, MPH, Director, Coordinating Center for Clinical Trials, National Institutes of Health, National Cancer Institute, Coordinating Center for Clinical Trials, 9609 Medical Center Drive, Room 6W136, Rockville, MD 20850, 240-276-6173, prindivs@mail.nih.gov.

    Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

    In the interest of security, NCI Shady Grove has instituted stringent procedures for entrance into the NCI Shady Grove building. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

    Information is also available on the Institute's/Center's home page: http://deainfo.nci.nih.gov/​advisory/​ctac/​ctac.htm, where an agenda and any additional information for the meeting will be posted when available.

    (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

    Start Signature

    Dated: February 11, 2019.

    Melanie J. Pantoja,

    Program Analyst, Office of Federal Advisory Committee Policy.

    End Signature End Preamble

    [FR Doc. 2019-02472 Filed 2-14-19; 8:45 am]

    BILLING CODE 4140-01-P

Document Information

Published:
02/15/2019
Department:
Health and Human Services Department
Agency:
National Institutes of Health
EntryType:
Notice
Document Number:
2019-02472
Dates:
July 17, 2019.
Pages:
4486-4487 (2 pages)
SectionNoes:
PDF File:
2019-02472.pdf